The research which was conducted by Jun Yan of University of Louisville School of Medicine in Louisville, Kentucky supports another study that found that differences in yeast-derived beta-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.
Biothera’s soluble beta-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T cell activation.
Yan said these data demonstrate how different beta-glucan structures affect immunomodulatory mechanisms.
"Biothera’s ability to produce and characterize these beta-glucan compounds was critical to this research," Yan said.
Biothera Research & Development senior vice president William Grossman said as demonstrated in previous research, ‘structure matters’ to beta-glucan binding and initiation of differential immunomodulatory responses.
"Our commitment to researching the biological mechanisms underpinning the activity of our compounds will lead to even more effective pharmaceuticals and food-grade ingredients," Grossman said.